Antiviral treatment attenuates hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma | EASL

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Antiviral treatment attenuates hepatitis B virus (HBV) reactivation after radiotherapy (RT) for hepatocellular carcinoma (HCC). 

Why this matters

  • There are no convincing data supporting the routine use of preventive therapy against hepatitis B virus (HBV) reactivation in radiotherapy (RT) for hepatocellular carcinoma (HCC). 

Key results

  • During the follow-up, 11 (9.1%) of 121 patients developed HBV reactivation.
  • Compared with the non-antiviral group, patients in the antiviral group had significantly lower rates of HBV reactivation (5.2% [5/97] vs 25% [6/24]; P=.002).
  • The incidence of HBV-induced radiation induced liver toxicity (RILT) (2.1% vs 12.5%; P=.021) and HBV related hepatitis (3.1% vs 12.5% P=.057) were low in the antiviral group.
  • In contrast, there was no difference in...